Δημοσιεύσεις

Έρευνα

2022-2024 (εώς σήμερα)

  1. Kassimis G, Mitsiadis S, Zormpas G, Boulmpou A, Vergopoulos S, Fragakis N. Contrast-enhanced echocardiography to define guidewire-related distal coronary artery perforation run-off and to rule out active intrapericardial bleeding. Postepy Kardiol Interwencyjnej. 2024 Mar;20(1):117-118. doi: 10.5114/aic.2024.137436. Epub 2024 Mar 22. PMID: 38616932; PMCID: PMC11008517 (IF 1.3).
  2. Karakasis P, Patoulias D, Giannakoulas G, Rosenkranz S, Fragakis N. Effect of sodium-glucose cotransporter-2 inhibitors on pulmonary arterial wedge pressure. Eur J Intern Med. Published online March 8, 2024. doi:10.1016/j.ejim.2024.03.003 (IF= 8)
  3. Karakasis P, Patoulias D, Kassimis G, Koufakis T, Klisic A, Doumas M, Fragakis N, Rizzo M. Therapeutic potential of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with acute coronary syndrome: a review of clinical evidence. Current Pharmaceutical Design. 2024. (IF= 3.1)
  4. Karakasis P, Patoulias D, Giannakoulas G, Fragakis N. Are we Ready for Expanding the Use of Sodium-glucose Co-transporter-2 Inhibitors in Patients with Acute Myocardial Infarction? Journal of Cardiovascular Pharmacology. 2024. (IF= 3)
  5. Karakasis P, Nasoufidou A, Sagris M, Fragakis N, Tsioufis K. Vascular Alterations Following COVID-19 Infection: A Comprehensive Literature Review. Life. 2024; 14(5):545. (IF= 3.2)
  6. Nasoufidou A, Papazoglou AS, Stachteas P, Karagiannidis E, Samaras A, Alexiou S, Mourtzos M-A, Kassimis G, Fragakis N. Intravenous Landiolol for Rate Control in Supraventricular Tachyarrhythmias in Patients with Left Ventricular Dysfunction: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2024; 13(6):1683. https://doi.org/10.3390/jcm13061683 [IF 5]
  7. Karakasis P. Comment on “Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis”. Curr Probl Cardiol. 2024;49(5):102520. doi:10.1016/j.cpcardiol.2024.102520 (IF= 4.2)
  8. Popovic DS, Karakasis P, Koufakis T, et al. Effect of sodium-glucose cotransporter-2 inhibitors on continuous glucose monitoring metrics, as adjunctive to insulin in adults with type 1 diabetes mellitus: a meta-analysis of randomized controlled trials. Metabolism. 2024;153:155791. doi:10.1016/j.metabol.2024.155791 (IF= 9.8)
  9. Pamporis K, Karakasis P, Sagris M, et al. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a network meta-analysis of 32 randomized trials. Curr Probl Cardiol. Published online April 29, 2024. doi:10.1016/j.cpcardiol.2024.102615 (IF= 4.2)
  10. Stachteas P, Nasoufidou A, Patoulias D, et al. The Role of Sodium-Glucose Co-Transporter-2 Inhibitors on Diuretic Resistance in Heart Failure. Int J Mol Sci. 2024;25(6):3122. Published 2024 Mar 8. doi:10.3390/ijms25063122 (IF= 5.6)
  11. Stachteas P, Karakasis P, Karagiannidis E, et al. Efficacy of sodium-glucose cotransporter 2 inhibitors in preventing AF recurrence after catheter ablation. Hellenic J Cardiol. Published online March 12, 2024. doi:10.1016/j.hjc.2024.03.008 (IF= 4.1)
  12. Karakasis P, Popovic DS, Patoulias D, Koufakis T, Papanas N, Fragakis N, Rizzo M. The Effect of Sodium-Glucose Cotransporter Inhibitors on Renal Function as Adjunctive to Insulin in Adults with Type 1 Diabetes: An Updated Multilevel Meta-analysis of Randomized Controlled Trials Diabetes Ther. 2024 Jan 5. doi: 10.1007/s13300-023-01523-0. Online ahead of print. [IF 3.4]
  13. Samaras A, Papazoglou AS, Balomenakis C, Bekiaridou A, Moysidis DV, Patsiou V, Orfanidis A, Giannakoulas G, Kassimis G, Fragakis N, Saw J, Landmesser U, Alkhouli MA, Tzikas A. Residual leaks following percutaneous left atrial appendage occlusion and outcomes: a meta-analysis Eur Heart J. 2023 Dec 13:ehad828. doi: 10.1093/eurheartj/ehad828. Online ahead of print. [IF 39.3]
  14. Karakasis P, Patoulias D, Fragakis N, Klisic A, Rizzo M. Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta-analysis Diabetes Obes Metab. 2023 Dec 20. doi: 10.1111/dom.15410. Online ahead of print. [IF 6.6]
  15. Karakasis P, Stalikas N, Patoulias D, Pamporis K, Karagiannidis E, Sagris M, Stachteas P, Bougioukas KI, Anastasiou V, Daios S, Apostolidou-Kiouti F, Giannakoulas G, Vassilikos V, Fragakis N, Giannopoulos G. Prognostic value of stress hyperglycemia ratio in patients with acute myocardial infarction: a systematic review with Bayesian and frequentist meta-analysis Trends Cardiovasc Med. 2023 Nov 30:S1050-1738(23)00107-X. doi: 10.1016/j.tcm.2023.11.006. Online ahead of print. [IF 9.3]
  16. Pamporis K, Karakasis P, Simantiris S, Sagris M, Bougioukas KI, Fragakis N, Tousoulis D. Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias’ treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network meta-analysis Clin Investig Arterioscler. 2023 Nov 30:S0214-9168(23)00100-6. doi: 10.1016/j.arteri.2023.11.003. Online ahead of print. [IF 1.6]
  17. Karakasis P, Patoulias D, Pamporis K, Stachteas P, Lefkou E, Bougioukas KI, Dimitroulas T, Fragakis N. Risk of subclinical atherosclerosis in primary Sjogren’s syndrome: A systematic review and meta-analysis Eur J Intern Med. 2023 Nov 15:S0953-6205(23)00396-5. doi: 10.1016/j.ejim.2023.11.007. Online ahead of print. [IF 5.7]
  18. Karakasis P, Bougioukas KI, Pamporis K, Fragakis N, Haidich AB. Appraisal methods and outcomes of AMSTAR 2 assessments in overviews of systematic reviews of interventions in the cardiovascular field: A methodological study Res Synth Methods. 2023 Nov 13. doi: 10.1002/jrsm.1680. Online ahead of print. [IF 9.3]
  19. Karakasis P, Patoulias D, Pamporis K, Stachteas P, Bougioukas KI, Klisic A, Fragakis N, Rizzo M. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials Metabolism. 2023 Dec;149:155710. doi: 10.1016/j.metabol.2023.155710. Epub 2023 Oct 16. [IF 9.8]
  20. Samaras A, Moysidis DV, Papazoglou AS, Rampidis G, Kampaktsis PN, Kouskouras K, Efthymiadis G, Ziakas A, Fragakis N, Vassilikos V, Giannakoulas G. Diagnostic Puzzles and Cause-Targeted Treatment Strategies in Myocardial Infarction with Non-Obstructive Coronary Arteries: An Updated Review J Clin Med. 2023 Sep 26;12(19):6198. doi: 10.3390/jcm12196198. [IF 5]
  21. Triantafyllou K, Fragakis N, Gatzoulis KA, Antoniadis A, Giannopoulos G, Arsenos P, Tsiachris D, Antoniou CK, Trachanas K, Tsimos K, Vassilikos V. Risk assessment of post-myocardial infarction patients with preserved ejection fraction using 45-min short resting Holter electrocardiographic recordings Ann Noninvasive Electrocardiol. 2023 Nov;28(6):e13087. doi: 10.1111/anec.13087. Epub 2023 Sep 12. [IF 1.9]
  22. Katritsis DG, Fragakis N, Katritsis G, Doukas V, Marine JE, Desmukh A, Latchamsetty R, Anderson RH, Calkins H. High-resolution mapping of the circuit of typical atrioventricular nodal reentrant tachycardia J Interv Card Electrophysiol. 2023 Sep 11. doi: 10.1007/s10840-023-01632-7. Online ahead of print. [IF 1.8]
  23. Karakasis P, Patoulias D, Pamporis K, Popovic DS, Stachteas P, Bougioukas KI, Fragakis N, Rizzo M. Efficacy and safety of once-weekly versus once-daily basal insulin analogues in the treatment of type 2 diabetes mellitus: A systematic review and meta-analysis Diabetes Obes Metab. 2023 Dec;25(12):3648-3661. doi: 10.1111/dom.15259. Epub 2023 Sep 5. [IF 6.6]
  24. Abramik J, Kontogiannis N, Scarsini R, De Maria GL, Raina T, Fragakis N, Kassimis G. Prognostic value of ΔSYNTAX% score in octogenarians undergoing percutaneous coronary intervention J Geriatr Cardiol. 2023 Jul 28;20(7):509-515. doi: 10.26599/1671-5411.2023.07.003. [IF 3.2]
  25. Patoulias D, Dimosiari A, Fragakis N. Tirzepatide for the treatment of heart failure in Type 2 diabetes mellitus: (SUR)PASS, or not? Future Cardiol. 2023 May;19(6):301-312. doi: 10.2217/fca-2022-0112. Epub 2023 Jul 21. [IF 1.7]
  26. Karakasis P, Patoulias D, Stachteas P, Lefkou E, Dimitroulas T, Fragakis N. Accelerated Atherosclerosis and Management of Cardiovascular Risk in Autoimmune Rheumatic Diseases: An Updated Review Curr Probl Cardiol. 2023 Dec;48(12):101999. doi: 10.1016/j.cpcardiol.2023.101999. Epub 2023 Jul 26. [IF 4.2]
  27. Kassimis G, Theodoropoulos KC, Didagelos M, Zegkos T, Fragakis N, Hadjimiltiades S, Ziakas A. Rotablation-assisted percutaneous coronary intervention and deferred intravascular lithotripsy: Facilitated stenting in a young STEMI patient with familial hypercholesterolemia Kardiol Pol. 2023;81(9):934-936. doi: 10.33963/KP.a2023.0160. Epub 2023 Jul 25. [IF 3.3]
  28. Karakasis P, Pamporis K, Stachteas P, Patoulias D, Bougioukas KI, Fragakis N. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an overview of 36 systematic reviews Heart Fail Rev. 2023 Sep;28(5):1033-1051. doi: 10.1007/s10741-023-10324-3. Epub 2023 Jun 7. [IF 4.6]
  29. Patoulias D, Popovic DS, Fragakis N, Rizzo M. Has the time come to step up to “triple therapy” for the treatment of diabetic kidney disease? Diabetes Res Clin Pract. 2023 Jul;201:110726. doi: 10.1016/j.diabres.2023.110726. Epub 2023 May 20. [IF 5.1]
  30. Samaras A, Kouparanis A, Didagelos M, Papadopoulos SF, Theodoropoulos KC, Ziakas A, Kassimis G. Iatrogenic aortocoronary dissection of a non-culprit right coronary artery during primary percutaneous coronary intervention in an ST-segment elevation myocardial infarction patient with Turner syndrome Coron Artery Dis. 2023 Jun 1;34(4):286-287. doi: 10.1097/MCA.0000000000001237. Epub 2023 Apr 7. [IF 1.4]
  31. Samaras A, Bekiaridou A, Papazoglou AS, Moysidis DV, Tsoumakas G, Bamidis P, Tsigkas G, Lazaros G, Kassimis G, Fragakis N, Vassilikos V, Zarifis I, Tziakas DN, Tsioufis K, Davlouros P, Giannakoulas G; CardioMining Study Group. Artificial intelligence-based mining of electronic health record data to accelerate the digital transformation of the national cardiovascular ecosystem: design protocol of the CardioMining study BMJ Open. 2023 Apr 3;13(4):e068698. doi: 10.1136/bmjopen-2022-068698. [IF 3]
  32. Patoulias D, Michailidis T, Dimosiari A, Fragakis N, Tse G, Rizzo M. Effect of Glucagon-like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors among Obese/Overweight Individuals Treated with Antipsychotic Drug Classes: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials Biomedicines. 2023 Feb 22;11(3):669. doi: 10.3390/biomedicines11030669. [IF 4.1]
  33. Sidiropoulos G, Antoniadis A, Saplaouras A, Bazoukis G, Letsas ΚP, Karamitsos TD, Giannopoulos G, Fragakis N. Impact of baseline right ventricular function on the response to cardiac resynchronization therapy – A meta-analysis Hellenic J Cardiol. 2023 Sep-Oct;73:61-68. doi: 10.1016/j.hjc.2023.03.002. Epub 2023 Mar 11. [IF 4.1]
  34. Karakasis P, Lefkou E, Pamporis K, Nevras V, Bougioukas KI, Haidich AB, Fragakis N. Risk of Subclinical Atherosclerosis in Patients with Antiphospholipid Syndrome and Subjects With Antiphospholipid Antibody Positivity: A Systematic Review and Meta-analysis Curr Probl Cardiol. 2023 Jun;48(6):101672. doi: 10.1016/j.cpcardiol.2023.101672. Epub 2023 Feb 24. [IF 4.2]
  35. Theodoropoulos KC, Kouparanis A, Didagelos M, Kassimis G, Ziakas A. Stent Damage Associated With a Guide Catheter Extension During Percutaneous Coronary Intervention J Invasive Cardiol. 2023 Feb;35(2):E101-E102. [IF 1.7]
  36. Giannopoulos G, Kousta M, Anagnostopoulos I, Karageorgiou S, Myrovali E, Deftereos G, Fragakis N, Siasos G, Vassilikos VP. Advances in Heart Failure with Preserved Ejection Fraction Management – The role of Sacubitril-Valsartan, Pirfenidone, Spironolactone and Empagliflozin: Is Success a Series of Small Victories? Curr Pharm Des. 2023 Feb 2. doi: 10.2174/1381612829666230202141437. Online ahead of print. [IF 3.1]
  37. Patoulias D, Fragakis N. The frail patient and the frailing heart. Letter regarding the article ‘Barcelona Bio-HF calculator version 3.0: recalibration and incorporation of sodium-glucose cotransporter 2 inhibitor treatment’ Eur J Heart Fail. 2023 Mar;25(3):441. doi: 10.1002/ejhf.2784. Epub 2023 Feb 2. [IF 18.2]
  38. Bakogiannis C, Mouselimis D, Tsarouchas A, Papadopoulos CE, Theofillogiannakos EK, Lechat E, Antoniadis AP, Pagourelias ED, Kelemanis I, Tzikas S, Fragakis N, Efthimiadis GK, Karamitsos TD, Doumas M, Vassilikos VP. Iron therapy and severe arrhythmias in HFrEF: rationale, study design, and baseline results of the RESAFE-HF trial ESC Heart Fail. 2023 Apr;10(2):1184-1192. doi: 10.1002/ehf2.14276. Epub 2023 Jan 17. [IF 3.8]
  39. Patoulias D, Fragakis N, Rizzo M. The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest Life (Basel). 2022 Dec 8;12(12):2062. doi: 10.3390/life12122062. [IF 3.2]
  40. Patoulias D, Kassimis G, Fragakis N. Sodium-glucose co-transporter-2 inhibitors, gut microbiota, and atherosclerotic cardiovascular disease: Another mountain to conquer? Pharmacol Res. 2023 Jan;187:106619. doi: 10.1016/j.phrs.2022.106619. Epub 2022 Dec 16. [IF 9.3]
  41. Samaras A, Papazoglou AS, Balomenakis C, Bekiaridou A, Moysidis DV, Rampidis GP, Kampaktsis PN, Apostolidou-Kiouti F, Haidich AB, Kassimis G, Kouskouras K, Fragakis N, Ziakas A, Vassilikos V, Giannakoulas G. Prognostic impact of secondary prevention medical therapy following myocardial infarction with non-obstructive coronary arteries: a Bayesian and frequentist meta-analysis Eur Heart J Open. 2022 Nov 23;2(6):oeac077. doi: 10.1093/ehjopen/oeac077. eCollection 2022 Nov. [IF -]
  42. Patoulias D, Michailidis T, Dimosiari A, Kassimis G, Fragakis N. Meta-analysis addressing the impact of sodium-glucose Co-transporter-2 inhibitors on the risk for atrial fibrillation among individuals with heart failure with preserved ejection fraction Int J Cardiol Cardiovasc Risk Prev. 2022 Nov 26;15:200161. doi: 10.1016/j.ijcrp.2022.200161. eCollection 2022 Dec. [IF 2.1]
  43. Alexiou S, Patoulias D, Theodoropoulos KC, Didagelos M, Nasoufidou A, Samaras A, Ziakas A, Fragakis N, Dardiotis E, Kassimis G. Intracoronary Thrombolysis in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: an Updated Meta-analysis of Randomized Controlled Trials Cardiovasc Drugs Ther. 2022 Nov 8. doi: 10.1007/s10557-022-07402-3. Online ahead of print. [IF 3.4]